Competition and FDA - Pharma Rep Focus

FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug

MedCity News

NOVEMBER 25, 2024

But new competition to both products could come soon from Alnylam Pharmaceuticals, now set to receive an FDA decision in this indication by late March. The post FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug appeared first on MedCity News.

FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug

Eli Lilly Alzheimer’s Drug Lands FDA Approval, Introducing Competition to Eisai’s Leqembi

Trending Sources

Full FDA Approval of Travere’s Kidney Drug Stiffens Competition With Novartis, Calliditas

New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds

FDA Approves Roche Lymphoma Drug, Bringing Competition to New AbbVie Med

Ionis Rare Disease Drug Is Headed to FDA, But Forthcoming Data Will Decide Competitive Profile

Sanofi’s FDA Nod in Hemophilia Gives Patients More Convenience, Brings Roche New Competition

FDA Approval of Mirati Lung Cancer Drug Sets Stage for Competition With Amgen

Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency

Autolus readies its CAR-T Aucatzyl to go after heavy hitter competition following FDA nod

Rare Disease Drug Approval Brings New Competition to Meds from Sanofi, Takeda

With FDA Nod for Colorectal Cancer Screening, How Much Market Share Can Guardant’s Blood Test Get?

FDA Approval of Pfizer Alopecia Drug Brings New Competition to Eli Lilly Med

Alnylam drug succeeds in heart study, setting stage for FDA filing and showdown with Pfizer

TheracosBio Drug Approval Puts It in Competition With Blockbuster Diabetes Meds

FTC Sees Red Over Alleged Misuse of FDA Orange Book, Puts 10 Pharmas on Notice

Jazz brings the noise to the FDA with lawsuit over approval of Avadel's narcolepsy drug Lumryx

FDA says no to Astellas' geographic atrophy drug

ESMO: Bristol Myers moves Opdualag into phase 3 trials in competitive first-line lung cancer field

Neuro Drug Passed Up by Biogen Posts Positive Data for Ionis, Setting Stage for Phase 3 Test

FDA competition seeks digital endpoints for Parkinson’s

In bispecific rivalry, AbbVie’s Epkinly follows Roche’s Lunsumio into follicular lymphoma

Biogen nabs FDA nod for biosimilar version of Roche's blockbuster Actemra

Roche burnishes breast cancer portfolio with FDA approval for Itovebi, a threat to Novartis and AZ

Competition is on the horizon for costly narcolepsy treatments

As Imbruvica stumbles, BeiGene's Brukinsa steps up with FDA nod in follicular lymphoma

J&J’s Tremfya, following in Stelara’s footsteps, enters crowded ulcerative colitis arena with FDA nod

Promising schizophrenia drug faces tough competition

Biosimilar competition saves US healthcare $21 billion

Is the launch environment really more competitive now?

Sandoz says its biosimilar matches Eylea in another threat to Regeneron's blockbuster

As donanemab nears FDA judgment day, Lilly embraces competition in Alzheimer's disease

Regeneron's Eylea HD passes key test in retinal vein occlusion, teeing up 2025 FDA filing as Eylea threats mount

FDA approves long-acting injectable for schizophrenia and bipolar disorder

The debate on DTC marketing is going to heat up again

Pharma Marketing Keyword Research for PPC

4D Molecular’s Fabry gene therapy program on FDA clinical hold

J&J's Rybrevant okay challenges Tagrisso in first-line NSCLC

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

FDA approves first Stelara biosimilar, Wezlana

FDA accepts AstraZeneca’s NDA for breast cancer combination therapy

FDA rejects Xspray's would-be rival to Bristol Myers' Sprycel on dosing, manufacturing concerns

FDA grants first approval for multiple sclerosis biosimilar

ESMO 2022: shrinking market for Trodelvy, with fierce ADC competition

Stay Connected